Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Current Deferred Revenue (2024 - 2025)

Xilio Therapeutics (XLO) has disclosed Current Deferred Revenue for 2 consecutive years, with $40.0 million as the latest value for Q4 2025.

  • Quarterly Current Deferred Revenue rose 196.07% to $40.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $40.0 million through Dec 2025, up 196.07% year-over-year, with the annual reading at $40.0 million for FY2025, 196.07% up from the prior year.
  • Current Deferred Revenue hit $40.0 million in Q4 2025 for Xilio Therapeutics, down from $43.8 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $70.9 million in Q2 2025 to a low of $13.5 million in Q4 2024.